Skip to content

A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?

Research output: Contribution to journalArticle

Standard

A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators? / Leung, Janni; Peacock, Amy; Colledge, Samantha; Grebely, Jason; Cunningham, Evan B; Hickman, Matthew; Vickerman, Peter; Stone, Jack; Trickey, Adam; Dumchev, Kostyantyn; Lynskey, Michael; Hines, Lindsey; Griffiths, Paul; Mattick, Richard P; Degenhardt, Louisa; Larney, Sarah.

In: Journal of Infectious Diseases, Vol. 220, No. 1, jiz058, 05.06.2019, p. 78-90.

Research output: Contribution to journalArticle

Harvard

Leung, J, Peacock, A, Colledge, S, Grebely, J, Cunningham, EB, Hickman, M, Vickerman, P, Stone, J, Trickey, A, Dumchev, K, Lynskey, M, Hines, L, Griffiths, P, Mattick, RP, Degenhardt, L & Larney, S 2019, 'A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?', Journal of Infectious Diseases, vol. 220, no. 1, jiz058, pp. 78-90. https://doi.org/10.1093/infdis/jiz058

APA

Vancouver

Author

Leung, Janni ; Peacock, Amy ; Colledge, Samantha ; Grebely, Jason ; Cunningham, Evan B ; Hickman, Matthew ; Vickerman, Peter ; Stone, Jack ; Trickey, Adam ; Dumchev, Kostyantyn ; Lynskey, Michael ; Hines, Lindsey ; Griffiths, Paul ; Mattick, Richard P ; Degenhardt, Louisa ; Larney, Sarah. / A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?. In: Journal of Infectious Diseases. 2019 ; Vol. 220, No. 1. pp. 78-90.

Bibtex

@article{f4acff412c3241d3b746373d4d70e258,
title = "A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?",
abstract = "BACKGROUND: Women-specific factors exist that increases vulnerability to drug-related harms from injection drug use, including blood-borne viruses (BBVs), but gender-based differences in BBV prevalence have not been systematically examined. METHODS: We conducted meta-analyses to estimate country, regional, and global prevalence of serologically confirmed human immunodeficiency virus (HIV), hepatitis C virus (HCV; based on detection of anti-HCV antibody), and hepatitis B virus (HBV; based on detection of HBV surface antigen) in people who inject drugs (PWID), by gender. Gender-based differences in the BBV prevalence (calculated as the risk among women relative to the risk among men) were regressed on country-level prevalence and inequality measures (Gender inequality index, Human development index, Gini coefficient, and high, low or middle income of the country). RESULTS: Gender-based differences varied by countries and regions. HIV prevalence was higher among women than men in sub-Saharan Africa (relative risk [RR], 2.8; 95{\%} confidence interval [CI], 1.8-4.4) and South Asia (RR, 1.7; 95{\%} CI, 1.1-2.7); anti-HCV was lower among women in the Middle East and North Africa (RR, 0.6; 95{\%} CI, .5-.7) and East and Southeast Asia (RR, 0.8; 95{\%} CI, .7-.9). Gender-based differences varied with country-levels of the BBV prevalence in the general population, human development, and income distribution. CONCLUSION: HIV was more prevalent in women who inject drugs as compared to their male counterparts in some countries, but there is variation between and within regions. In countries where women are at higher risks, there is a need to develop gender-sensitive harm-reduction services for the particularly marginalized population of women who inject drugs.",
keywords = "HIV, hepatitis b, hepatitis c antibodies, gender, viruses, drug usage, gender differences, women who inject drugs, injecting drug use, substance use, intravenous, HIV seroprevalence, HBV, HCV, hepatitis, blood-borne virus, blood born pathogens",
author = "Janni Leung and Amy Peacock and Samantha Colledge and Jason Grebely and Cunningham, {Evan B} and Matthew Hickman and Peter Vickerman and Jack Stone and Adam Trickey and Kostyantyn Dumchev and Michael Lynskey and Lindsey Hines and Paul Griffiths and Mattick, {Richard P} and Louisa Degenhardt and Sarah Larney",
year = "2019",
month = "6",
day = "5",
doi = "10.1093/infdis/jiz058",
language = "English",
volume = "220",
pages = "78--90",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

RIS - suitable for import to EndNote

TY - JOUR

T1 - A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?

AU - Leung, Janni

AU - Peacock, Amy

AU - Colledge, Samantha

AU - Grebely, Jason

AU - Cunningham, Evan B

AU - Hickman, Matthew

AU - Vickerman, Peter

AU - Stone, Jack

AU - Trickey, Adam

AU - Dumchev, Kostyantyn

AU - Lynskey, Michael

AU - Hines, Lindsey

AU - Griffiths, Paul

AU - Mattick, Richard P

AU - Degenhardt, Louisa

AU - Larney, Sarah

PY - 2019/6/5

Y1 - 2019/6/5

N2 - BACKGROUND: Women-specific factors exist that increases vulnerability to drug-related harms from injection drug use, including blood-borne viruses (BBVs), but gender-based differences in BBV prevalence have not been systematically examined. METHODS: We conducted meta-analyses to estimate country, regional, and global prevalence of serologically confirmed human immunodeficiency virus (HIV), hepatitis C virus (HCV; based on detection of anti-HCV antibody), and hepatitis B virus (HBV; based on detection of HBV surface antigen) in people who inject drugs (PWID), by gender. Gender-based differences in the BBV prevalence (calculated as the risk among women relative to the risk among men) were regressed on country-level prevalence and inequality measures (Gender inequality index, Human development index, Gini coefficient, and high, low or middle income of the country). RESULTS: Gender-based differences varied by countries and regions. HIV prevalence was higher among women than men in sub-Saharan Africa (relative risk [RR], 2.8; 95% confidence interval [CI], 1.8-4.4) and South Asia (RR, 1.7; 95% CI, 1.1-2.7); anti-HCV was lower among women in the Middle East and North Africa (RR, 0.6; 95% CI, .5-.7) and East and Southeast Asia (RR, 0.8; 95% CI, .7-.9). Gender-based differences varied with country-levels of the BBV prevalence in the general population, human development, and income distribution. CONCLUSION: HIV was more prevalent in women who inject drugs as compared to their male counterparts in some countries, but there is variation between and within regions. In countries where women are at higher risks, there is a need to develop gender-sensitive harm-reduction services for the particularly marginalized population of women who inject drugs.

AB - BACKGROUND: Women-specific factors exist that increases vulnerability to drug-related harms from injection drug use, including blood-borne viruses (BBVs), but gender-based differences in BBV prevalence have not been systematically examined. METHODS: We conducted meta-analyses to estimate country, regional, and global prevalence of serologically confirmed human immunodeficiency virus (HIV), hepatitis C virus (HCV; based on detection of anti-HCV antibody), and hepatitis B virus (HBV; based on detection of HBV surface antigen) in people who inject drugs (PWID), by gender. Gender-based differences in the BBV prevalence (calculated as the risk among women relative to the risk among men) were regressed on country-level prevalence and inequality measures (Gender inequality index, Human development index, Gini coefficient, and high, low or middle income of the country). RESULTS: Gender-based differences varied by countries and regions. HIV prevalence was higher among women than men in sub-Saharan Africa (relative risk [RR], 2.8; 95% confidence interval [CI], 1.8-4.4) and South Asia (RR, 1.7; 95% CI, 1.1-2.7); anti-HCV was lower among women in the Middle East and North Africa (RR, 0.6; 95% CI, .5-.7) and East and Southeast Asia (RR, 0.8; 95% CI, .7-.9). Gender-based differences varied with country-levels of the BBV prevalence in the general population, human development, and income distribution. CONCLUSION: HIV was more prevalent in women who inject drugs as compared to their male counterparts in some countries, but there is variation between and within regions. In countries where women are at higher risks, there is a need to develop gender-sensitive harm-reduction services for the particularly marginalized population of women who inject drugs.

KW - HIV

KW - hepatitis b

KW - hepatitis c antibodies

KW - gender

KW - viruses

KW - drug usage

KW - gender differences

KW - women who inject drugs

KW - injecting drug use

KW - substance use

KW - intravenous

KW - HIV seroprevalence

KW - HBV

KW - HCV

KW - hepatitis

KW - blood-borne virus

KW - blood born pathogens

UR - http://www.scopus.com/inward/record.url?scp=85067440591&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiz058

DO - 10.1093/infdis/jiz058

M3 - Article

VL - 220

SP - 78

EP - 90

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

M1 - jiz058

ER -